Company Description
Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States.
The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.
It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs.
The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Charles L. Pope CPA |
Contact Details
Address: 1990 Main Street, Suite 750 Sarasota, Florida 34236 United States | |
| Phone | (813) 286-7900 |
| Website | oragenics.com |
Stock Details
| Ticker Symbol | OGEN |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001174940 |
| CUSIP Number | 684023500 |
| ISIN Number | US6840235005 |
| Employer ID | 59-3410522 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Charles L. Pope CPA | Executive Chairman |
| Joseph Michael Redmond | President and Interim Principal Executive Officer |
| Janet Huffman | Chief Financial Officer, Secretary and Treasurer |
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer and Member of Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 424B5 | Filing |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 27, 2024 | FWP | Free Writing Prospectus |
| Feb 27, 2024 | 424B5 | Filing |